Resveratrol was used to be adopted by old schools of medicine like the Chinese and Japanese medical schools as an important remedy in their traditional medicine tenets [1]. Resveratrol fluency is seen in plant sources; especially those of red leafs and others, for example grapes, weed roots, peanuts, berries and red wines [2]. Resveratrol is capable of protecting the previously mentioned plants against the fungal and bacterial plant infections, hence they are rich with it [3]. Resveratrol belongs to family of phenolic and stilbenes, with a great potency as antioxidant [4], and therapeutic propensities against diseases and protective capability against different diseases like cancer [5], inflammations [6], aging [7], infertility [8], antihyperlipidemic [9] and many others [10]. 

The total blood cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triacylglycerols are the main targeted indicators for the elevation disorder of lipids within blood or as they are aggregately called hyperlipidemia. [11]. Hydroxy methyl glutaryl co-enzyme A reductase inhibitors, are group or vast family of medications, used for treating elevations of lipoids in the blood, those medication groups are called statins; compromising lovastatin and rosuvastatin [12]. This designed study was to evaluate the resveratrol against the statins considering different blood parameters.               

Animals of the Experiment

Fifty male laboratory rats of 180–225 gram weights were targeted. The experiment continued for two months.

Groups

• Group One:  A ten-rat group was maintained on a standard diet for two months. A standard rat diet was administered to the animals. [13]

• Group Two: (Cholesterol (T1). The ten male rats were fed a meal containing cholesterol at a dosage of 15 grams per kilogram of feed. The incorporation of cholesterol into the diet was founded upon [14]

• Group Three: (Rosuvastatin (T2). Ten male rats were administered cholesterol at a dose of 15g/kg of feed in a standard diet. rats received an oral dosage of 20 mg/kg body weight of rosuvastatin using an oral gavage on a single day. The selection of the rosuvastatin dosage was depend on previous study findings. [15]

• Group Four: (Lovastatin (T3). A group of ten male rats was fed a standard diet with 15 grams of cholesterol per kilogram of feed; Furthermore. the rats received a dosage of 4 milligrams of lovastatin per kilogram of body weight orally once a day by gavage administration. The dosage of lovastatin was determined depending on prior studies. [16]

• Group Five :(Resveratrol (T4). A group of ten male rats was fed with a standard diet that was enriched with cholesterol at a dosage of 15 grams per kilogram of feed. They were given a daily oral dose of 60 mg/kg of resveratrol by gavage. The resveratrol dosage was selected depending on prior studies. [17]

Study Parameters

The research included the use of a specialized instrument known as DONGI 120 for all of its testing., which used gathered blood sera.

Statistical Analysis

The analysis of variance (ANOVA) technique was adopted to figure out the (least significant difference) among the groups.

The study results have demonstrated that cholesterol led to a substantial elevation in the count of red blood cells (RBC), the concentration of hemoglobin (HGB), the volume of packed red blood cells (HCT), and the overall count of white blood cells (WBC). Rosuvastatin resulted in a substantial reduction in hemoglobin (HGB), hematocrit (HCT), and white blood cells (WBC), whereas Lovastatin alone produced a significant drop in leukocytes. Resveratrol resulted in no significant variations in any of the metrics when compared to the control group., table 1. 

Table 1: Hematological Effects Of Resveratrol Comparing With Statins

Elevated cholesterol levels resulted in a notable rise in neutrophil count and a substantial decrease in lymphocyte and monocyte counts. Rosuvastatin and Lovastatin resulted in a notable elevation in neutrophil count, along with a considerable reduction in monocytes and lymphocytes. However, the levels of acidophils and basophils were unaffected. The parameters of resveratrol showed no significant alterations as compared to the control group. table 2. 

Table 2. Effects Of Resveratrol On Leukocytes Count Comparing With Statins

The platelets count and platelets indices; the count was significantly increased by cholesterol while both the statins and resveratrol did not affect them table 3. 

Table 3: Effects of Resveratrol on Platelets Indices Comparing With Statins

The erythrocytes blood indices were not affected by all the treatment groups, table 4.

Table 4: Effects Of Resveratrol On Erythrocytes Indices Comparing With Statins

Many previous studies like [18-20] come in line with this study considering the effects of statins. Numerous prior investigations corroborate resveratrol's function, including [21]. Because it inhibits reactive oxygen species, resveratrol has a high antioxidant efficacy. [22]. Resveratrol permits protection to the cells against free radicals [23]. Resveratrol is also capable of forbidding platelets from being coalesce [24]. Resveratrol can inhibit lipid peroxidation [25 and 26]. Finally, based on the previous properties of resveratrol, it can be considered as a good choice to be depended.

Based upon the obtained results, one can easily conclude the following:

• Statins could cause declination in the blood lipids but they could cause deleterious effects on other lipid and cellular aspects

• Resveratrol can be a safe source as a protector against oxidative stress and lipid fluctuations

1. Baxter R.A. “Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation.” J Cosmet Dermatol, vol. 1, no. 1, 2008, pp. 2–7.

2. Menjoge A.R. and Kannan R.M. “Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications.” Drug Discov Today, vol. 15, no. 3, 2010, pp. 171–185.

3. Esfand R. and Tomalia D.A. “Poly (amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.” Drug Discov Today, vol. 6, no. 7, 2001, pp. 427–436.

4. Frankel E.N. et al. “Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine.” Lancet, vol. 341, no. 8843, 1993, pp. 454–457.

5. Gautam S.C. et al. “Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging.” Bone Marrow Transplant, vol. 25, no. 6, 2000, pp. 639–645.

6. Wang Z. et al. “Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro.” Int J Mol Med, vol. 9, no. 1, 2002, pp. 77–79.

7. Zern T.L. et al. “Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs.” J Nutr, vol. 133, no. 7, 2003, pp. 2268–2272.

8. Piver B. et al. “Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non-volatile red wine components.” Toxicol Lett, vol. 125, no. 2–3, 2001, pp. 83–91.

9. Lekakis J. et al. “Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease.” Eur J Cardiovasc Prev Rehabil, vol. 12, no. 6, 2005, pp. 596–600.

10. Sato M. et al. “Myocardial protection with red wine extract.” J Cardiovasc Pharmacol, vol. 35, no. 2, 2000, pp. 263–268.

11. Nelson R.H. “Hyperlipidemia as a risk factor for cardiovascular disease.” Prim Care, vol. 40, no. 2, 2013, pp. 195–211.

12. Vaughan C.J. and Gotto A.M. “The evolving role of statins in the management of atherosclerosis.” J Am Coll Cardiol, vol. 35, no. 1, 2000, pp. 1–10.

13. Subcommittee of Laboratory Animal Nutrition, Committee on Animal Nutrition, Board on Agriculture, and National Research Council. “Nutrient requirements of laboratory animals.” National Academy Press, 4th ed., 1995.

14. Choi M.J. et al. “The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high cholesterol diet.” Adv Exp Med Biol, vol. 6, 2006, pp. 235–242.

15. Harish K.V.S. et al. “Effect of rosuvastatin as an anti-inflammatory agent in albino rats.” Asian J Pharm Clin Res, vol. 4, no. 2 (Suppl.), 2011, pp. 74–76.

16. Gile R.D. et al. “Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat.” Am J Kidney Dis, vol. 26, no. 3, 1995, pp. 501–507.

17. Zhang G. et al. “The effect of resveratrol on blood glucose and blood lipids in rats with gestational diabetes mellitus.” Evid Based Complement Alternat Med, vol. 2021, 2021, pp. 2956795.

18. Hashim W.S. et al. “Physiological study about rosuvastatin and lovastatin as compared with quercetin in rats (Rattus norvegicus).” J Glob Pharma Technol, vol. 11, no. 5 (Suppl.), 2019, pp. 28–32.

19. Gillett R.C. and Norrell A. “Consider diets for safe use of statins: liver enzyme abnormalities and muscle toxicity.” Am Fam Physician, vol. 83, no. 6, 2011, pp. 1–6.

20. Taleb H.M. et al. “The effect of rosuvastatin on liver function among patients with coronary heart disease in Gaza Strip.” Pharmacol Pharm, vol. 5, no. 9, 2014, pp. 781–788.

21. Al-Uboody W.S. and Al-Diwan M.A. “Study the protective role of quercetin against o-anisidine toxicity on some hematological parameters of laboratory male rats (Rattus norvegicus).” Bas J Vet Res, vol. 14, no. 1, 2015, pp. 1–10.

22. Bradamante S. et al. “Cardiovascular protective effects of resveratrol.” Cardiovasc Drug Rev, vol. 22, no. 3, 2004, pp. 169–188.

23. Wang Q. et al. “Resveratrol protects against global cerebral ischemic injury in gerbils.” Brain Res, vol. 958, no. 2, 2002, pp. 439–447.

24. Sinha K. et al. “Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats.” Life Sci, vol. 71, no. 6, 2002, pp. 655–665.

25. Howitz K.T. et al. “Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.” Nature, vol. 425, no. 6954, 2003, pp. 191–196.